Use and efficacy of bone morphogenetic proteins in fracture healing

International Orthopaedics

Volumn 35, Issue 9, 2011, Pages 1271-1280

  Lissenberg Thunnissen, Suzanne N ^a   De Gorter, David J J ^a   Sier, Cornelis F M ^a   Schipper, Inger B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN; COLLAGEN SPONGE; ENDOGLIN; FETUIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFUSE; MONOCLONAL ANTIBODY; NOGGIN; OP 1 PUTTY; RECOMBINANT BONE MORPHOGENETIC PROTEIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 6; RECOMBINANT BONE MORPHOGENETIC PROTEIN 9; RECOMBINANT CYTOKINE; RECOMBINANT OSTEOGENIC PROTEIN 1; SCLEROSTIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACETABULUM FRACTURE; ANTIBODY PRODUCTION; BONE DEVELOPMENT; BONE DISEASE; BONE REMODELING; BONE TRANSPLANTATION; CALCIFICATION; CHONDROGENESIS; CLINICAL TRIAL (TOPIC); COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISTRACTION OSTEOGENESIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; ECTOPIC BONE FORMATION; EMBASE; FIBULA FRACTURE; FRACTURE; FRACTURE FIXATION; FRACTURE HEALING; FRACTURE NONUNION; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; MEDLINE; NEGATIVE FEEDBACK; NONHUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RISK BENEFIT ANALYSIS; SCAPHOID FRACTURE; SIDE EFFECT; SIGNAL TRANSDUCTION; SOFT TISSUE DISEASE; SOFT TISSUE SWELLING; SYSTEMATIC REVIEW; THROMBOCYTE RICH PLASMA; TIBIA FRACTURE; WORK RESUMPTION;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE REGENERATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FRACTURE HEALING; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; TREATMENT OUTCOME;

EID: 80655144424     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-011-1301-z     Document Type: Review

References (92)

1. Meling T, Harboe K, Søreide K (2009) Incidence oftraumatic long-bone fractures requiring in-hospital management: a prospective age-and gender-specific analysis of4890 fractures. Injury 40:1212-1219
2. Tosounidis T, Kontakis G, Nikolaou V, Papathanassopoulos A, Giannoudis PV (2009) Fracture healing and bone repair: an update. Trauma 11:145-156
3. Court-Brown CM, Bucholz RW, Heckman JD (2005) Fractures of the tibia and fibula. Rockwood and Green's fractures in adults. Lippincott Williams & Wilkins, Philadelphia, pp 2079-2146
4. Dimitriou R, Tsiridis E, Giannoudis PV (2005) Current concepts ofmolecular aspects ofbone healing. Injury 36:1392-1404 (Pubitemid 41618169)
5. Komatsu DE, Warden SJ (2010) The control of fracture healing and its therapeutic targeting: improving upon nature. J Cell Biochem 109:302-311
6. Urist MR (1965) Bone: formation by autoinduction. Science 150:893-899
7. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA (1988) Novel regulators of bone formation: molecular clones and activities. Science 242:1528-1534 (Pubitemid 19023695)
8. Vukicevi? S, Stavljeni? A, Pe?ina M (1995) Discovery and clinical applications of bone morphogenetic proteins. Eur J Clin Chem Clin Biochem 33:661-671
9. Li JZ, Li H, Sasaki T, Holman D, Beres B, Dumont RJ, Pittman DD, Hankins GR, Helm GA (2003) Osteogenic potential of five different recombinant human bone morphogenetic protein adeno-viral vectors in the rat Gene Ther 10:1735-1743 (Pubitemid 37121045)
10. Tsiridis E, Upadhyay N, Giannoudis P (2007) Molecular aspects of fracture healing: which are the important molecules? Injury 38 (Suppl 1):S11-S25 (Pubitemid 46440926)
11. Miyazono K, Kamiya Y, Morikawa M (2010) Bone morphogenetic protein receptors and signal transduction. J Biochem 147:35-51
12. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS (1996) Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science 271:360-362
13. Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM (2001) Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27:84-88 (Pubitemid 32044524)
14. Shen B, Bhargav D, Wei A, Williams LA, Tao H, Ma DD, Diwan AD (2009) BMP-13 emerges as a potential inhibitor of bone formation. Int J Biol Sci 5:192-200
15. Sipe JB, Zhang J, Waits C, Skikne B, Garimella R, Anderson HC (2004) Localization of bone morphogenetic proteins (BMPs)-2,-4, and-6 within megakaryocytes and platelets. Bone 35:1316-1322 (Pubitemid 40267635)
16. Pecina M, Vukicevic S (2007) Biological aspects of bone, cartilage and tendon regeneration. Int Orthop 31:719-720 (Pubitemid 350160315)
17. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC (2003 Osteogenic activity of the fourteen types of human bone morphoge-netic proteins (BMPs). J Bone Joint Surg Am 85-A:1544-1552 (Pubitemid 36951140)
18. Rosen V (2006) BMP and BMP inhibitors in bone. Ann N YAcad Sci 1068:19-25 (Pubitemid 43824133)
19. Song K, Krause C, Shi S, Patterson M, Suto RK, Grgurevic L, Vukicevic S, van Dinther M, Falb D, Ten Dijke P, Alaoui-Ismaili MH (2010) Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem 285:12169-12180
20. Cunningham NS, Jenkins NA, Gilbert DJ, Copeland NG, Reddi AH, Lee SJ (1995) Growth/differentiation factor-10: a new member of the transforming growth factor-beta superfamily related to bone mor-phogenetic protein-3. Growth Factors 12:99-109
21. Dimitriou R, Tsiridis E, Carr I, Simpson H, Giannoudis PV (2006) The role of inhibitory molecules in fracture healing. Injury 37 (Suppl 1):S20-S29 (Pubitemid 44316774)
22. Heinke J, Wehofsits L, Zhou Q, Zoeller C, Baar KM, Helbing T, Laib A, Augustin H, Bode C, Patterson C, Moser M (2008) BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res 103:804-812
23. Dean DB, Watson JT, Moed BR, Zhang Z (2009) Role of bone morphogenetic proteins and their antagonists in healing of bone fracture. Front Biosci 14:2878-2888
24. Tsialogiannis E, Polyzois I, Oak Tang Q, Pavlou G, Tsiridis E, Heliotis M, Tsiridis E (2009) Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opin Ther Targets 13:123-137
25. Gamer LW, Cox K, Carlo JM, Rosen V (2009) Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures. Dev Dyn 238:2374-2381
26. Wilkinson L, Kolle G, Wen D, Piper M, Scott J, Little M (2003) CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem 278:34181-34188 (Pubitemid 37553260)
27. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J, Niehrs C (1999) Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401:480-485 (Pubitemid 29470206)
28. Ishibashi O, Ikegame M, Takizawa F, Yoshizawa T, Moksed MA, Iizawa F, Mera H, Matsuda A, Kawashima H (2010) Endoglin is involved in BMP-2-induced osteogenic differentiation of peri-odontal ligament cells through a pathway independent of Smad-1/ 5/8 phosphorylation. J Cell Physiol 222:465-473
29. Pardali E, van der Schaft DW, Wiercinska E, Gorter A, Hogendoorn PC, Griffioen AW, ten Dijke P (2011) Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 30:334-345
30. Sapkota G, Alarcón C, Spagnoli FM, Brivanlou AH, Massagué J (2007) Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell 25:441-454 (Pubitemid 46199289)
31. Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, De Robertis EM (2007) Integrating patterning signals: Wnt/ GSK3 regulates the duration of the BMP/Smad1 signal. Cell 131:980-993 (Pubitemid 350138081)
32. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y Arbel R, Aro H, Atar D, Bishay M, Börner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, Mc Coy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Rüter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T et al (2002) Recom-binant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A:2123-2134 (Pubitemid 35417689)
33. Calori GM, Tagliabue L, Gala L, d Imporzano M, Peretti g, Albisetti W (2008) Application of rh BMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients. Injury 39:1391-1402
34. Giannoudis PV, Tzioupis C (2005) Clinical applications of BMP-7: the UK perspective. Injury 36(Suppl 3):S47-S50
35. Katayama Y, Matsuyama Y, Yoshihara H, Sakai Y Nakamura H, Imagama S, Ito Z, Wakao N, Kamiya M, Yukawa Y, Kanemura T Sato K, Iwata H, Ishiguro N (2009) Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study. Int Orthop 33:1061-1067
36. Varady P, Li JZ, Cunningham M, Beres EJ, Das S, Engh J, Alden TD, Pittman DD, Kerns KM, Kallmes DF, Helm GA (2001) Morphologic analysis of BMP-9 gene therapy-induced osteogen-esis. Hum Gene Ther 12:697-710 (Pubitemid 32506947)
37. Yilgor P, Hasirci N, Hasirci V (2010) Sequential BMP-2/BMP-7 delivery from polyester nanocapsules. J Biomed Mater Res A 93:528-536
38. Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY García AJ, Guldberg RE (2011) Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 32:5241-5251
39. Valentin-Opran A, Wozney J, Csimma C, Lilly L, Riedel GE (2002) Clinical evaluation of recombinant human bone morpho-genetic protein-2. Clin Orthop Relat Res 395:110-120 (Pubitemid 34136661)
40. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, Mc Kee MD (2007) Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 31:735-741 (Pubitemid 350160312)
41. Geesink RG, Hoefnagels NH, Bulstra SK (1999) Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 81:710-718
42. Bilic R, Simic P, Jelic M, Stern-Padovan R, Dodig D, van Meerdervoort HP, Martinovic S, Ivankovic D, Pecina M, Vuki-cevic S (2006) Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis. Int Orthop 30:128-134
43. Ristiniemi J, Flinkkilä T, Hyvönen P, Lakovaara M, Pakarinen H, Jalovaara P (2007) Rh BMP-7 accelerates the healing in distal tibial fractures treated by external fixation. J Bone Joint Surg Br 89:265-272 (Pubitemid 46421481)
44. Barr T Mc Namara AJ, Sándor GK, Clokie CM, Peel SA (2010) Comparison of the osteoinductivity of bioimplants containing recombinant human bone morphogenetic proteins 2 (Infuse) and 7 (OP-1). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:531-540
45. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, Song F, Alt V (2010) Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 6: CD006950
46. Bishop GB, Einhorn TA (2007) Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop 31:721-727 (Pubitemid 350160314)
47. Mines D, Gu Y Kou TD, Cooper GS (2011) Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospec-tive cohort study. Pharmacoepidemiol Drug Saf 20:111-118
48. Tazaki J, Murata M, Akazawa T, Yamamoto M, Ito K, Arisue M, Shibata T Tabata Y (2009) BMP-2 release and dose-response studies in hydroxyapatite and beta-tricalcium phosphate. Biomed Mater Eng 19:141-146
49. Alt V, Haas H, Rauschmann MA, Carstens C, Franke J, Eicher A, Bitschnau A, Schnettler R (2006) Health-economic considerations for the use of BMP-2 for spinal surgery in Germany (in German). Z Orthop Ihre Grenzgeb 144:577-582 (Pubitemid 46118848)
50. Dahabreh Z, Calori GM, Kanakaris NK, Nikolaou VS, Giannoudis PV (2009) A cost analysis oftreatment oftibial fracture nonunion by bonegraftingorbonemorphogenetic protein-7. Int Orthop 33:1407-1414
51. Garrison KR, Donell S, Ryder J, Shemilt I, Mugford M, Harvey I, Song F (2007) Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 11:1-150, iii-iv
52. Kanakaris NK, Giannoudis PV (2007) The health economics of the treatment of long-bone non-unions. Injury 38(Suppl 2):S77-S84 (Pubitemid 47498409)
53. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A et al (2006) Recombinant human BMP-2 and allograft compared with autog-enous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88:1431-1441
54. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, La Forte AJ, Yin S (2001) Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment oftibial nonunions. J Bone Joint Surg Am 83-A(Suppl 1):S151-S158
55. von Einem S, Schwarz E, Rudolph R (2010) A novel TWO-STEP renaturation procedure for efficient production of recombinant BMP-2. Protein Expr Purif 73:65-69
56. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949 (Pubitemid 129515901)
57. Pauly S, Luttosch F, Morawski M, Haas NP, Schmidmaier G, Wildemann B (2009) Simvastatin locally applied from a biode-gradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone 45:505-511
58. Rittenberg B, Partridge E, Baker G, Clokie C, Zohar R, Dennis JW, Tenenbaum HC (2005) Regulation of BMP-induced ectopic bone formation by Ahsg. J Orthop Res 23:653-662 (Pubitemid 40631339)
59. Wan DC, Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM, Harland R, Blau HM, Longaker MT (2007) Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 282:26450-26459 (Pubitemid 47443797)
60. Ten Dijke P, Krause C, De Gorter DJ, Lowik CW, Van Bezooijen RL (2008) Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 90 Suppl 1:31-5 (Pubitemid 351329118)
61. Kang Q, Sun MH, Cheng H, Peng Y Montag AG, Deyrup AT Jiang W, Luu HH, Luo J, Szatkowski JP, Vanichakarn P, Park JY,Li Y, Haydon RC, He TC (2004) Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11:1312-1320 (Pubitemid 39213996)
62. Jane JA Jr, Dunford BA, Kron A, Pittman DD, Sasaki T, Li JZ, Li H, Alden TD, Dayoub H, Hankins GR, Kallmes DF, Helm GA (2002) Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther 6:464-470 (Pubitemid 35214867)
63. Grasser WA, Orlic I, Borovecki F, Riccardi KA, Simic P, Vukicevic S, Paralkar VM (2007) BMP-6 exerts its osteoinductive effect through activation of IGF-I and EGF pathways. Int Orthop 31:759-765 (Pubitemid 350160308)
64. Helm GA, Alden TD, Beres EJ, Hudson SB, Das S, Engh JA, Pittman DD, Kerns KM, Kallmes DF (2000) Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg 92:191-196 (Pubitemid 30207415)
65. Dumont RJ, Dayoub H, Li JZ, Dumont AS, Kallmes DF, Hankins GR, Helm GA (2002) Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery 51:1239-1244
66. Majumdar MK, Wang E, Morris EA (2001) BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1. J Cell Physiol 189:275-284 (Pubitemid 33063295)
67. Zhu W, Rawlins BA, Boachie-Adjei O, Myers ER, Arimizu J, Choi E, Lieberman JR, Crystal RG, Hidaka C (2004) Combined bone morphogenetic protein-2 and-7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 19:2021-2032 (Pubitemid 41103417)
68. Zhu W, Kim J, Cheng C, Rawlins BA, Boachie-Adjei O, Crystal RG, Hidaka C (2006) Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 39:61-71 (Pubitemid 43831779)
69. Valera E, Isaacs MJ, Kawakami Y, Izpisúa Belmonte JC, Choe S (2010) BMP-2/6 heterodimer is more effective than BMP-2 or BMP-6 homodimers as inductor of differentiation of human embryonic stem cells. PLoS One 5:e11167
70. Alliston T Choy L, Ducy P, Karsenty G, Derynck R (2001) TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 20:2254-2272 (Pubitemid 32410595)
71. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K (2004) Endogenous TGF-beta signaling suppresses maturation of osteo-blastic mesenchymal cells. EMBO J 23:552-563 (Pubitemid 38282387)
72. de Gorter DJ, van Dinther M, Korchynskyi O, ten Dijke P (2011) Biphasic effects of transforming growth factor-beta on bone morphogenetic protein-induced osteoblast differentiation. J Bone Miner Res 26:1178-1187
73. Tachi K, Takami M, Sato H, Mochizuki A, Zhao B, Miyamoto Y Tsukasaki H, Inoue T, Shintani S, Koike T, Honda Y Suzuki O, Baba K, Kamijo R (2011) Enhancement of bone morphogenetic protein-2-induced ectopic bone formation by transforming growth factor-beta1. Tissue Eng Part A 17:597-606
74. Cho TJ, Gerstenfeld LC, Einhorn TA (2002) Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 17:513-520 (Pubitemid 34171766)
75. Yu YY Lieu S, Lu C, Miclau T, Marcucio RS, Colnot C (2010) Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair. Bone 46:841-851
76. Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233-241 (Pubitemid 40136452)
77. Vainio S, Karavanova I, Jowett A, Thesleff I (1993) Identification of BMP-4 as a signal mediating secondary induction between epithelial and mesenchymal tissues during early tooth develop-ment. Cell 75:45-58 (Pubitemid 23306020)
78. Bessa PC, Cerqueira MT, Rada T, Gomes ME, Neves NM, Nobre A, Reis RL, Casal M (2009) Expression, purification and osteogenic bioactivity of recombinant human BMP-4,-9,-10,-11 and-14. Protein Expr Purif63:89-94
79. Kingsley DM, Bland AE, Grubber JM, Marker PC, Russell LB, Copeland NG, Jenkins NA (1992) The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF beta superfamily Cell 71:399-410
80. Bobacz K, Gruber R, Soleiman A, Erlacher L, Smolen JS, Graninger WB (2003) Expression of bone morphogenetic protein 6 in healthy and osteoarthritic human articular chondrocytes and stimulation ofmatrix synthesis in vitro. Arthritis Rheum 48:2501-2508 (Pubitemid 37129427)
81. Vukicevic S, Grgurevic L (2009) BMP-6 and mesenchymal stem cell differentiation. Cytokine Growth Factor Rev 20:441-448
82. Dudley AT, Lyons KM, Robertson EJ (1995) A requirement for bone morphogenetic protein-7 during development of the mam-malian kidney and eye. Genes Dev 9:2795-2807
83. Luo G, Hofmann C, Bronckers AL, Sohocki M, Bradley A, Karsenty G (1995) BMP-7 is an inducer ofnephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 9:2808-2820
84. Di Leone RJ, King JA, Storm EE, Copeland NG, Jenkins NA, Kingsley DM (1997) The Bmp8 gene is expressed in developing skeletal tissue and maps near the Achondroplasia locus on mouse chromosome 4. Genomics 40:196-198 (Pubitemid 27108272)
85. Song JJ, Celeste AJ, Kong FM, Jirtle RL, Rosen V, Thies RS (1995) Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology 136:4293-4297
86. López-Coviella I, Berse B, Krauss R, Thies RS, Blusztajn JK (2000) Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science 289:313-316 (Pubitemid 30469912)
87. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Löwik CW, ten Dijke P (2007) BMP-9 signals via ALK1 and inhibits b FGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120:964-972 (Pubitemid 46638511)
88. Chen H, Shi S, Acosta L, Li W, Lu J, Bao S, Chen Z, Yang Z, Schneider MD, Chien KR, Conway SJ, Yoder MC, Haneline LS, Franco D, Shou W (2004) BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 131:2219-2231 (Pubitemid 38702052)
89. Fu SC, Wong YP, Chan BP, Pau HM, Cheuk YC, Lee KM, Chan KM (2003) The roles of bone morphogenetic protein (BMP) 12in stimulating the proliferation and matrix production of human patellar tendon fibroblasts. Life Sci 72:2965-2974 (Pubitemid 36423375)
90. Storm EE, Huynh TV, Copeland NG, Jenkins NA, Kingsley DM, Lee SJ (1994) Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily Nature 368:639-643 (Pubitemid 24153388)
91. Dube JL, Wang P, Elvin J, Lyons KM, Celeste AJ, Matzuk MM (1998) The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes. Mol Endocrinol 12:1809-1817 (Pubitemid 28544177)
92. Feiner N, Begemann G, Renz AJ, Meyer A, Kuraku S (2009) The origin ofbmp16, a novel Bmp2/4 relative, retained in teleost fish genomes. BMC Evol Biol 9:277